Whitehawk (WHWK) CEO Lennon James Receives 387,914-Share Awards

What Happened
Lennon David James, CEO of Whitehawk Therapeutics, received two derivative awards on September 15, 2026: one award of 193,957 shares and a second award of 193,957 shares (totaling 387,914 shares). Both grants are recorded at $0.00 (no cash paid at grant). One award is structured as restricted stock units (RSUs) (each RSU converts to one share on vesting) and the other appears to be an option-like award; both are subject to multi‑year vesting schedules described in the filing.

Key Details

• Transaction date: 2026-09-15; Report filed: 2026-09-15 (appears timely).
• Grants: two derivative awards of 193,957 shares each; total potential shares = 387,914. Price per share at grant: $0.00 (no cash paid at grant).
• Shares owned after transaction: not disclosed in the provided data.
• Vesting / notable footnotes:
  • F2: Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F1 (option-style award): 25% vests on the one‑year anniversary of the Vesting Commencement Date, then 1/48th of total shares vests each month thereafter (fully vested after four years). Vesting Commencement Date = September 15, 2026.
  • F3 (award/RSU schedule): 25% vests on each of the next four annual anniversaries (i.e., 25% per year over four years).
• Filing timeliness: Reported and filed on 2026-09-15 (no late‑filing indication in the provided info).

Context
These were compensation/retention awards (derivative grants), not open‑market buys or sales. RSUs are contingent rights that convert to shares only upon vesting; the option‑style award vests over time and would require exercise (and possibly payment of an exercise price) before obtaining shares. Such grants increase potential future share dilution but do not represent immediate share sales or purchases by the insider.